In vitro reactivity and in vivo biodistribution of the monoclonal antibody A7 using human gastric carcinoma cell lines. by Yamaoka, N. et al.
Br. J. Cancer (1994), 70, 405-408 C) Macmillan Press Ltd.,
In vitro reactivity and in vivo biodistribution of the monoclonal antibody
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S_nmary The monoclonal antibody (MAb) A7 has been used to treat patients with colorectal or pancreatic
carcinoma with encouraging results. We therefore determined if MAb A7 would also react with gastric
carcinoma cell lines. MAb A7 reacted with seven of eight gastric carcinoma cell lines tested. The intensity of
the reaction, measured by flow cytometry, was equal to that of WiDr (colon) and HPC-YS (pancreas) cell
lines. In nude mice bearing xenografts of the MAb A7-reactive gastric cancer line MKN45, the percentage
injected dose of MAb A7 per g of tumour tissue on day 7 was 9.79; this value was 77% of that on day 1. The
in vivo tumour-to-blood ratio of MAb A7 was 2.77 on day 7. Therefore, MAb A7 has long-term retention at
binding sites as well as a high probability, high intensity and high specificity of reactivity against gastric
cancer, which make it an ideal drug carrier for immunotargeted chemotherapy and immunodiagnosis.
Many gastric cancers are now detected at an early stage,
mainly because of mass screening and recent improvements
in gastrofibrescopic endoscopy. Early gastric cancers now
account for almost 50% of clinically detected gastric cancers
in Japan (Bollschweiler et al., 1993) and 95% of patients with
early gastric cancer can be cured by surgery (Inoue et al.,
1991; Moriguchi et al., 1991). Gastric cancer remains the
most common carcinoma in Japan (Tominaga, 1987). Thus,
there are still many advanced cases of gastric cancer that lead
to death despite surgical treatment and chemotherapy. Ultra-
sound tomography, computerised tomography (CT) and
angiography are routinely used in the staging of gastric
cancer. But their sensitivity and specificity limit their ability
in preoperative staging and evaluating the completeness of a
resection.
One possible approach to overcome the limitations of both
current chemotherapy and present diagnostic techniques is to
attach anti-cancer agents or radionuclei to monoclonal
antibodies (MAbs) against various solid tumours, so that a
drug or radioactive isotope can be selectively confined to
tumour cells (Tjandra et al., 1989; Boeckmann et al., 1990;
Elias et al., 1990; Jan-Erik et al., 1990; Hani et al., 1991). We
have developed MAb A7 against a human colonic carcinoma
(Kotanagi et al., 1986) and have covalently combined MAb
A7 with the anticancer antibiotic neocarzmnostatin (NCS) to
produce a MAb-drug conjugate, A7-NCS. A7-NCS has a
significant anti-tumour effect on grafted human colonic car-
cinoma in nude mice. We have already treated patients with
colorectal carcinoma with A7-NCS and have obtained en-
couraging results. An early A7-NCS trial has shown that
three of eight patients with post-operative liver metastasis
showed evidence of tumour reduction on CT scan, and three
obtained pain relief without severe adverse effects (Takahashi
et al., 1988). Furthermore, A7-NCS treatment prolonged
survival time when compared with conventional chemo-
therapy in the patients with liver metastasis (median survival
times: A7-NCS group, 328 days; conventional chemotherapy
group, 128 days; P<0.05) (Takahashi et al., 1993). Further-
more, in our recent study, MAb A7 was shown to react with
77% of human pancreatic carcinoma cell lines as well as with
human colonic carcinoma (Otsuji et al., 1990, 1993). This
suggests that MAb A7 may react with several kinds of
carcinoma, e.g. gastric carcinoma, and that MAb
A7-antitumour agent conjugates may have a favourable
effect on those carcinomas.
In this study, we investigated the in vitro reactivity of MAb
A7 with eight gastric carcinoma cell lines using flow cyto-
metry, and also examined the in vivo biodistribution of MAb
A7 using human gastric cancer xenografts in nude mice in
order to determine their therapeutic and diagnostic usefulness
in a preclinical model.
Matrials and method
Cell lines
The human gastric carcinoma cell lines MKN1 (adeno-
squamous carcinoma), MKN28 (moderately differentiated
adenocarcinoma), MKN45 (poorly differentiated adenocar-
cinoma), MKN74 (well-differentiated adenocarcinoma),
NUGC2 (moderately differentiated adenocarcinoma),
NUGC3 (moderately differentiated adenocarcinoma), AZ521
(moderately differentiated adenocarcinoma) and KATO III
(signet ring cell carcinoma), the human colonic carcinoma
cell line WiDr and the human pancreatic carcinoma cell line
HPC-YS were used in this study. All ofthe gastric carcinoma
cell lines and WiDr were generously provided by JCRB
(Japanese Cancer Research Resources Bank, Tokyo). HPC-
YS was a kind gift from N. Yamaguchi (Department of
Research, Institute of Neurology and Geriatrics, Kyoto
Prefectural University of Medicine) (Yamaguchi et al., 1990).
All the cell lines were maintained in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Flow Laboratories, Rockville, MD, USA).
Monoclonal antibodies
The murine monoclonal antibody MAb A7 was developed
against huan colonic carcinoma as described previously
(Kotanagi et al., 1986). MAb A7 has been shown to react
with a 45 kDa surface glycoprotein of human colonic car-
cinomas (Kitamura et al., 1989) and 77% of the human
pancreatic carcinoma cell lines tested, including HPC-YS.
The A7 antigen loses antigenic activity after sodium
periodate, pronase and ficin treatments. MAb A7 does not
react with normal gastric mucosa, erythrocytes, peripheral
lymphocytes or ileal mucosa, and has weak reactivity with
10% of colon mucosa specimens (Kotanagi et al., 1986).
Normal mouse IgG was purchased from Boehringer Mann-
heim Biochemicals (Mannheim, Germany).
Cellfixation andstaining
For immunostaining, I x 106 cells were incubated in 2 ml of
phosphate-buffered saline (PBS) containing 30 Ig ml-' MAb
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A7 and 1% bovine serum albumin (BSA) (Sigma, St Louis,
MO, USA) for 1 h at 37C, washed twice with PBS and fixed
in 50% methanol at -20C for 15 min. After fixation, cells
were washed and incubated for 30 min with fluorescein
isothiocyanate (FITC)-labelled rabbit anti-mouse antibody
(Dako, Denmark) diluted 1:40 in PBS containing 1% BSA.
The cells were washed once in PBS, resuspended in
lIOfgml-' propiodium iodide (PI) (Sigma) and 1 mgml-'
RNAse A (Sigma) in PBS, and incubated at room
temperature for 30 min prior to flow cytometry.
Flow cytometry
Samples were analysed on a FACScan flow cytometer (Bec-
ton Dickinson, USA) equipped with a 15 mW air-cooled
488 nm argon ion laser. Green fluorescence was collected
after a 530 nm bandpass filter. PI emissions were filtered
through a 585 nm bandpass filter. Electronic compensation
was used to remove residual spectral overlap. The reactivity
to MAb A7 was measured by FITC fluorescence, and DNA
content was measured simultaneously by PI fluorescence. All
data were stored in list mode and analysed with a CellFit
operating system (Becton Dickinson) and Lysis operating
system (Becton Dickinson). Doublets and debris were gated
out from the red peak vs integral dot plot. Data from 30,000
events were collected in the final gated histogram.
Results
In vitro reactivity ofgastric cancer cell lines
MAb A7 reacted with seven of the eight gastric carcinoma
cell lines tested (87%) (Figure 1). Only MKN1, an adeno-
squamous carcinoma, did not react with MAb A7. The mean
fluorescence cell intensity of each of the seven gastric cancer
cell lines was equal to that of the colonic cancer cell line
WiDr and the pancreatic cancer cell line HPC-YS.
As shown in Figure 2, the cell surface of MKN45 and
KATO III was stained with MAb A7 FITC immunofluore-
scence staining and a cell nucleus was dyed with PI. By
contrast, in the case of MKNI, the cell surface was not
stained, only a cell nucleus was dyed by PI.
In vivo distribution ofradiolabelled antibodies
More radiolabelled MAb A7 accumulated in the grafted
MKN45 tumours than in the blood after day 3, and high
radioactivity was maintained until day 7 (Figure 3). On the
other hand, less radiolabelled normal mouse IgG
accumulated in the tumour than in the blood at all times. In
contrast, in mice harbouring MKN1 both radiolabelled IgG
and MAb A7 localised less in the tumour than in the blood
at all points of study (Figure 4).
Preparation ofradiolabelled MAbs
MAb A7 and normal mouse IgG labelled with "2I (IMS 30,
Amersham Japan) were obtained by the chloramine-T
method (Hunter & Greenwood, 1962). The iodinated MAb
A7 was separated from excess reactants by gel filtration on a
Sephadex G25 column (Pharmacia, Sweden). The specific
activities of the ['"I]MAb A7 and 'MI-labelled normal mouse
IgG were 1.2 to 1.3 sCi;Lg-' respectively.
Twnour xenograft
Cultured MKN45 cells were harvested by ethylenediamine-
tetraacetic acid (EDTA) treatment, washed in PBS and re-
suspended in PBS. Approximately 1 x 107 viable cells were
injected subcutaneously into the left flank of 8-week-old
athymic nude mice (Balb/c, nu/nu, male, mean body weight
approximately 21 g) (SLC, Shizuoka, Japan). A tumour mass
was detected in each mouse injected with MKN45 cells
(tumour weight 226 ± 32 mg, diameter approximately 8 mm).
MKN1 cells were also inoculated into the mice by the same
method as a negative control (tumour weight 187 ± 28 mg,
diameter approximately 7 mm).
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Figwe 1 In vitro reactivity of gastric cancer cell lines with the
anti-human colon carcinoma antibody MAb A7. MAb A7
reacted with seven of eight gastric carcinoma cell lines (87%).
Only MKNI was not recognised by MAb A7. The mean intensity
of cdll fluorescence of the gastric cancer cell lines was equal to
that of WiDr and HPC-YS.
In vivo distribution ofradiolabelledantibodies
The human gastric cancer-bearing nude mice were injected
intravenously with 0.7IACi of either '"I-labelled A7 or "I-
labelled normal mouse IgG. Four mice from each group were
sacrificed and dissected on days 1, 3, 5 and 7. After dissec-
tion, the tumours, blood, lungs, heart, liver, spleen, pancreas,
stomach, small intestine, colon and kidneys were weighed.
Radioactivity in the tissues was measured using a gamma
scintillation counter (Auto-Gamma 5000, Packard, IL, USA).
The results from the various tissues were expressed as
c.p.m. g-' and compared with those for normal mouse IgG.
To compare the specific localisation of MAb A7 in the
tumour with that in the normal tissues, the ratio of radioac-
tivity in these tissues to that in the blood was calculated.
These ratios were derived by dividing the radioactivity in the
various tissues on a per weight basis by that in the total
blood on a per weight basis. The Student's t-test was used to
check for statistically significant differences. A P-value of less
than 0.05 was considered to be statistically significant.
The distribution of the antibodies in the tumours was also
measured by the same method using nude mice harbouring
MKN1 tumours.
Fugwe 2 Immunofluorescence staining of the gastric cancer cell
lines MKN45, KATO In and MKNI by MAb A7. I x 106 cells
wer reacted with 30Mg kg-' MAb A7 as described in the
Materials and methods section. The cell surface of MKN45 and
KATO III stains with MAb A7 and a cell nucklus was dyed with
PI. By contrast, in the case of MKN1, the cell surface was not
stained, only a cell nucleus was dyed by PI. Left: MKN45.
Middle: KATO HI. Right: MKN1.
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Figure 3 The distribution of '2I-labelled MAb A7 in the blood
(open symbols) and tumours (closed symbols) of mice bearing
MKN45 tumours after intravenous injection. Human gastric
cancer MKN45-bearing nude mice were injected intravenously
with 0.71Ci of either '"I-labelled A7 (circles) or '"W-labelled
normal mouse IgG (triangles). Four mice from each group were
sacrificed and dissected on days 1, 3, 5 and 7. The radioactivity in
the tumour and in the blood was measured using a gamma
scintillation counter and expressed as c.p.m. g-' tissue.
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Fue 4 Distribution of '"I-labelled MAb A7 in the blood and
tumours of mice bearing MKN1 tumours after the intravenous
injection. The amount of radioactivity in the blood and in the
tumours of mice harbouring MKNI is shown. Mice were injected
and radioactivity was measured as in Figure 3. Symbols as in
Figure 3.
The MAb A7 tumour-to-blood ratio rose progressively to
2.77 ± 0.19 on day 7 (Figure 5). In contrast, the values in
normal organs were all below 0.38 ± 0.09 and did not change
over time. The normal mouse IgG tumour-to-blood ratio
ranged from 0.25 ± 0.07 to 0.32 ± 0.06 during this experi-
ment. The difference in tumour-blood ratio between the two
groups was statistically significant.
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We have used the monoclonal antibody (MAb) A7 as a drug
or radioactive isotope carrier to treat colorectal and pan-
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Figre 5 Tissue-blood ratios of "5I-labelled MAb A7 in nude
mice bearing human gastric cancer xenografts. Tissue-blood
ratios of "2I-labelled MAb A7 and "NI-labelled normal mouse
IgG on days 1, 3, 5 and 7 are shown. These ratios were derived
from dividing the radioactivity in the various tissues on a per
weight basis by that in the total blood on a per weight basis. a,
MKN45 tumour-bearing mice. b, MKNI tumour-bearing mouse.
Mice were injected and radioactivity was measured as described
in the Materials and methods section.
creatic cancers. In this study, we evaluated the possibility of
using MAb A7 in gastric cancer treatment and diagnosis. If
Mab A7 is to be useful for immunotargeted chemotherapy
and for imaging with radiolabelled monoclonal antibodies in
patients with gastric carcinoma, it will be necessary to docu-
ment that MAb A7 has a high probability, high intensity and
high specificity of binding to gastric cancer cells, as well as
long-term retention at the binding sites.
Histological heterogeneity is a characteristic feature of gas-
tric cancer that differs from colorectal cancer. In this report,
we studied the reactivity of MAb A7 with various histo-
logical types of cancer cell lines. MAb A7 reacted with the
common types of gastric cancer cells regardless of the degree
of differentiation, but it did not react with the adeno-
squamous carcinoma cell line, MKN1. It has been previously
reported that MAb A7 does not react with a squamous cell
carcinoma cell line, KB-2 (Otsuji et al., 1992). However, the
common types are the absolute majority of all gastric car-
cinomas. Therefore, MAb A7 has a high probability of reac-
ting with gastric carcinoma.
According to our flow cytometry measurements, the in
vitro intensity of the reactivity with the common types of
gastnc carcinoma cell lines was as high as that with the
colonic carcinoma cell line WiDr and the pancreatic car-
cinoma cell line HPC-YS. Moreover, the in vivo percentage
injected dose per g of tumour tissue of MAb A7 to MKN45
on day 7 was 9.79. Those of the colonic carcinoma cell line
Colon 6 and the pancreatic carcinoma cell line HPC-YS on
day 8 were 8.18 and 3.3 respectively (Takahashi, 1985; Otsuji
et al., 1992). These findings indicate that MAb A7 has a high
intensity of reactivity with gastric carcinoma, similar to its
reactivity with colonic and pancreatic carcinoma.
The in vivo tumour-to-blood ratio of MAb A7 is a good
index of the specificity of MAb A7. The tumour-to-blood
ratio of MKN45 on day 7 was 2.77, 8.65 times that of
normal mouse IgG. The ratio in the colonic carcinoma cell
line Colon 6 was 2.38 on day 8 and was 2.04 in the pan-
creatic carcinoma cell line HPC-YS (Takahashi, 1985; Otsuji
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et al., 1992). The tissue-to-blood ratio of each of the normal
organs was significantly lower than the tumour-to-blood
ratio, and no difference between MAb A7 and normal mouse
IgG was found. These findings indicate that MAb A7 has a
high specificity for gastric carcinoma, similar to that for
colonic and pancreatic carcinomas. Reintgen et al. (1983)
have reported that an antibody tumour-blood ratio must be
greater than 2-10 for reliable tumour imaging, and Tsuda et
al. (1990) have successfully performed immunoscintigraphy
of tumour xenografts in nude mice after injection of an
'3'I-labelled MAb. which achieves a tumour tissue-blood
ratio of 3.1. Moreover, the low distribution of A7 to normal
organs may lead to a low incidence of side-effects during
therapy and low background during diagnostic scinti-
graphy.
The in vivo percentage injected dose of MAb A7 per g of
tumour tissue on day 7 was 77% of that on day 1. This
shows that MAb A7 is retained at the binding sites, and
means that the dose of the anti-tumour agent which is carried
out by MAb A7 could be decreased, and would not have to
be administered frequently, which may also reduce the
incidence of side-effects.
Recently, Sickle-Santanello et al. (1987) have developed a
hand-held gamma detection probe for intraoperative use. The
aim of radical surgery for gastric cancer is to provide an
uninvolved surgical margin and lymph nodes. However, in
practice, tissues dissected during this procedure may not be
involved pathologically. A radioimmuno-guided procedure
using MAbs may be useful for determining the extent of a
gastric cancer.
In conclusion, MAb A7 has the characteristics of an ideal
drug carrier for immunotargeted chemotherapy and radio-
labelled monoclonal antibody imaging of gastric cancer. We
expect that MAb A7 will prove clinically useful for the
treatment of gastric carcinoma.
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